DermTech (NASDAQ:DMTK) insider Todd Michael Wood sold 1,345 shares of the business’s stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $10.82, for a total value of $14,552.90. Following the sale, the insider now directly owns 166,122 shares of the company’s stock, valued at $1,797,440.04. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Shares of DMTK stock opened at $11.39 on Wednesday. The stock has a market cap of $222.12 million, a PE ratio of -5.72 and a beta of 0.77. The stock has a 50-day moving average of $11.59 and a 200-day moving average of $12.38. DermTech has a one year low of $5.06 and a one year high of $16.95.
DermTech (NASDAQ:DMTK) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.21). The company had revenue of $0.84 million during the quarter. DermTech had a negative net margin of 599.76% and a negative return on equity of 69.48%.
Several hedge funds have recently made changes to their positions in DMTK. Strs Ohio bought a new stake in shares of DermTech in the 2nd quarter valued at about $27,000. Morgan Stanley acquired a new position in shares of DermTech in the 1st quarter valued at approximately $32,000. UBS Group AG grew its position in shares of DermTech by 25,700.0% in the 2nd quarter. UBS Group AG now owns 2,580 shares of the company’s stock valued at $34,000 after purchasing an additional 2,570 shares during the period. American International Group Inc. acquired a new position in shares of DermTech in the 2nd quarter valued at approximately $66,000. Finally, New York State Common Retirement Fund acquired a new position in shares of DermTech in the 2nd quarter valued at approximately $98,000. 50.06% of the stock is owned by institutional investors.
Several analysts have weighed in on the company. Brookline Capital Management assumed coverage on DermTech in a report on Friday, September 11th. They set a “buy” rating for the company. ValuEngine cut DermTech from a “buy” rating to a “hold” rating in a report on Wednesday, August 26th. Finally, Cowen assumed coverage on DermTech in a report on Thursday, September 10th. They set an “outperform” rating and a $20.00 price objective for the company.
DermTech, Inc, a molecular genomics company, develops and markets novel non-invasive diagnostic tests to diagnosis skin cancer and related conditions in the United States. The company offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions.
Further Reading: Shanghai Stock Exchange Composite Index
Receive News & Ratings for DermTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DermTech and related companies with MarketBeat.com's FREE daily email newsletter.